Episode
Saad Alam (CEO, Hone Health) - Longevity, testosterone, & peptides
- Podcast
- Hims House
- Published
- Oct 14, 2025
- Duration seconds
- 3085
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/saad-alam-ceo-hone-health-longevity-testosterone-peptides/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/saad-alam-ceo-hone-health-longevity-testosterone-peptides.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In episode 48 of Hims House, Jonathan Stern and Patrick Lester (Bayside) are joined by Saad Alam, founder & CEO of Hone Health. The discussion dives into Saad’s personal health journey and the founding of Hone Health during the pandemic. Saad discusses the company’s focus on hormonal health, weight loss, thyroid medications, and new longevity medications. Saad shares insights into diagnostics, the future of primary care, implications of the Meta ad privacy policy changes and FDA advertising crackdown, and the future of the telehealth industry. 00:43 Saad’s personal health journey 02:34 Hone’s products, revenue, competitors 04:29 Enclomiphene vs. clomiphene 09:07 Testosterone market and demographics 14:10 What longevity means 19:25 Lab testing and biomarkers 22:09 Why Hone hasn’t offered GLP-1s 25:14 “Everyone has a Chinese peptide dealer now” 33:53 Which peptides should Hims start with 35:38 Meta ads and the FDA crackdown on ads 40:43 Is primary care in trouble? 47:52 Why Saad is bullish on Hims Get full access to Hims House at himshouse.substack.com/subscribe